Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer

被引：2
|
作者：
Wander, S. A.
Spring, L. M.
Stein, C. R.
Yuen, M.
Zangardi, M.
O'Shaughnessy, J.
Bardia, A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-39
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
    Wander, Seth Andrew
    Zangardi, Mark
    Niemierko, Andrzej
    Kambadakone, Avinash
    Kim, Leslie S. L.
    Xi, Jing
    Pandey, Apurva Kumari
    Spring, Laura
    Stein, Casey
    Juric, Dejan
    Kuter, Irene
    Moy, Beverly
    Mulvey, Therese Marie
    Vidula, Neelima
    Isakoff, Steven J.
    Yuen, Megan
    Brufsky, Adam
    Ma, Cynthia X.
    O'Shaughnessy, Joyce
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [3] SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2-breast cancer
    Van Geelen, Courtney T.
    Teo, Zhi Ling
    Savas, Peter
    Luen, Stephen J.
    Clarke, Kylie A.
    Sant, Sneha
    Cowley, Karla J.
    Caramia, Franco
    Simpson, Kaylene J.
    Andre, Fabrice
    Dawson, Sarah-Jane
    Pearson, Richard
    Loi, Sherene
    CANCER RESEARCH, 2023, 83 (05)
  • [4] A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2-breast cancer
    Tolaney, S. M.
    Sahebjam, S.
    Le Rhun, E.
    Lin, Nu
    Bear, M. Markel
    Yang, Z.
    Chen, Y.
    Anders, C. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [6] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
  • [7] Metastatic HR+/HER2-Breast Cancer Real-World Data support the clinical Benefits of Palbociclib
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [8] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer
    Hurvitz, S.
    Martin, M.
    Fernandez Abad, M.
    Chan, D.
    Rostorfer, R.
    Petru, E.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Nguyen, T.
    Press, M.
    Slamo, D.
    CANCER RESEARCH, 2017, 77
  • [10] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
12345